Every Medicare Part D plan maintains its own formulary — the specific list of drugs it covers — and that list is not fixed for the life of a policy. Plans are permitted to revise formularies each new plan year, which begins every January 1, and a medication a beneficiary has taken and had covered for years can be removed, moved to a more expensive cost tier, or made subject to a new restriction with the arrival of the new year. Medicare.gov’s own description of drug coverage is explicit that “each plan has its own formulary,” a detail that becomes consequential only when a beneficiary discovers, often at the pharmacy counter in January, that the plan chosen the previous fall no longer covers a drug it covered in December.
The formulary is reset annually, and the plan controls what’s on it
Medicare does not set a single national drug list; each private plan builds its own formulary within federal minimum-coverage rules, and Medicare’s own guidance confirms plans must cover a wide range of drugs commonly used by people with Medicare, including most drugs in certain protected classes such as cancer, HIV/AIDS, and depression treatments — but “a wide range” is not “every drug,” and coverage outside those protected classes is left largely to each plan’s own formulary committee. A plan can add, remove, or re-tier a non-protected-class drug from one plan year to the next without violating any minimum-coverage requirement, as long as the overall formulary still meets Medicare’s baseline standards.
The practical effect is that loyalty to a specific Part D plan does not guarantee continuity of coverage for a specific drug. A beneficiary who has stayed with the same plan for years because switching felt unnecessary can still see a formulary change every January, since the plan’s formulary is revised annually regardless of whether the beneficiary re-enrolls, stays put, or actively compares options during the fall Open Enrollment period.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
Mid-year drops are restricted; the real risk window is the January reset
Part D plans face tighter limits once a plan year is underway. Medicare’s drug-plan-rules page describes a transition fill — a one-time, 30-day supply a new enrollee can receive for a drug the new plan doesn’t cover or restricts — as a safety net specifically for the disruption a formulary change or a plan switch can cause. According to consumer guidance from the Medicare Rights Center’s Medicare Interactive project, plans generally cannot make a negative formulary change during the first 60 days of a new plan year except in narrow cases, such as an FDA safety action, and after that window a plan making a negative change must generally give affected members 30 days’ written notice or a one-month supply under the transition rule.
Those mid-year protections do not apply to the January 1 reset itself, which is exactly when the most consequential formulary changes typically take effect. A plan’s Annual Notice of Change, sent each September, is required to disclose the coming year’s formulary changes before Open Enrollment closes, which means the protection against being blindsided is procedural and time-limited: it depends on a beneficiary actually reading a notice that arrives months before the change takes effect, during the same fall window when nearly every other Medicare enrollment decision also demands attention.
Plans use specific tools to restrict a drug without removing it outright
A formulary change is not always a flat removal. Medicare’s plan-rules page describes prior authorization, which requires a prescriber to justify medical necessity before the plan will cover a drug; step therapy, which requires trying a less expensive drug first before the plan covers a more expensive one for the same condition; and quantity limits, which cap how much of a drug the plan covers over a given period — the page’s own example caps coverage at 30 tablets a month, a ceiling that causes no problem for a once-daily dose but can leave a beneficiary on a twice-daily regimen short of a full month’s supply unless a prescriber documents why the higher quantity is medically necessary. A plan can leave a drug technically on the formulary while attaching any of these restrictions for the new plan year, producing the same practical effect as a removal — a beneficiary who could fill a prescription without any extra step in December may need a new prior authorization or a documented step-therapy failure to fill the same prescription in January.
Every one of these restrictions comes with a formal exception process, in which a prescriber submits a statement explaining why the beneficiary needs the specific drug despite the plan’s requirement, but the process takes time to complete and is not guaranteed to succeed. For a beneficiary who depends on a specific medication without interruption, the annual formulary reset means the safest habit is not trusting an unchanged premium or an unchanged plan name as a sign that a specific drug’s coverage carried over — the only reliable check is comparing the actual January formulary, tier, and any new restriction against what applied the previous December.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
